Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 4 April 2025, including: pharma dodges tariffs for now; Marks’s departure from FDA rattles industry; Phase 2b win for AstraZeneca’s oral PCSK9; Hengrui renews global Phase 3 push; and Novo’s new cardio results for semaglutide.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, , SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
This episode was produced with the assistance of AI-powered text-to-speech and speech emulation tools.
Stories mentioned in this episode:
- Pharma Exhales, Dodging A Financial Blow With Tariff Exemption
- Peter Marks’ Departure From FDA Rattles Biopharma Industry
- AstraZeneca Oral PCSK9 Prospects Pumped After Phase IIb Win
- Hengrui Renews Global Phase III Push As China Players Plan Pivotal Multinational Trials
- Novo Scores Cardio Wins But Lilly Still Tipped To Take GLP-1 Crown
